Seminars in Nuclear Medicine
Volume 31, Issue 4 , Pages 321-329 , October 2001

Imaging hypoxia in tumors

  • James R. Ballinger

      Affiliations

    • Corresponding Author InformationAddress reprint requests to James R. Ballinger, PhD, Department of Nuclear Medicine, Box 170, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, England.

References 

  1. Gray LH, Conger AD, Ebert M, et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26:638–648
  2. Bush RS, Jenkin RDT, Allt WEC, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer. 1978;37:302–306
  3. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6:509–518
  4. Voute PA, van der Kleij AJ, De Kraker J, et al. Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer. 1995;31A:596–600
  5. Kinuya S, Yokoyama K, Konishi S, et al. Improved response of colon cancer xenografts to radioimmunotherapy with pentoxifylline treatment. Eur J Nucl Med. 2001;28:750–755
  6. Brown JM, Giaccia AJ. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 1998;58:1408–1416
  7. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 1996;379:88–91
  8. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res. 1996;56:5754–5757
  9. Brown JM. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. Mol Med Today. 2000;6:157–162
  10. Hockel M, Knoop C, Schlenger K, et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol. 1993;26:45–50
  11. Wong RK, Fyles A, Milosevic M, et al. Heterogeneity of polarographic oxygen tension measurements in cervix cancer: An evaluation of within and between tumor variability, probe position, and track depth. Int J Radiat Oncol Biol Phys. 1997;39:405–412
  12. Bussink J, Kaanders JH, Strik AM, et al. Optical sensor-based oxygen tension measurements correspond with hypoxia marker binding in three human tumor xenograft lines. Radiat Res. 2000;154:547–555
  13. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervical cancer. Radiother Oncol. 1998;48:149–156
  14. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 1996;41:31–39
  15. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38:285–289
  16. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56:941–943
  17. Movsas B, Chapman JD, Greenberg RE, et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age. Cancer. 2000;89:2018–2024
  18. Fyles AW, Milosevic M, Pintilie M, et al. Cervix cancer oxygenation measured following external radiation therapy. Int J Radiat Oncol Biol Phys. 1998;42:751–753
  19. Rofstad EK, Sundfor K, Lyng H, et al. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer. 2000;83:354–359
  20. Chapman JD. Hypoxic sensitizers—Implications for radiation therapy. N Engl J Med. 1979;301:1429–1432
  21. Hodgkiss RJ. Use of 2-nitroimidazoles as bioreductive markers for tumor hypoxia. Anti-Cancer Drug Des. 1998;13:687–702
  22. Evans SM, Joiner B, Jenkins WT, et al. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br J Cancer. 1995;72:875–882
  23. Thrall DE, Rosner GL, Azuma C, et al. Hypoxia marker labeling in tumor biopsies: Quantification of labeling variation and criteria for biopsy sectioning. Radiother Oncol. 1997;44:171–176
  24. Varia MA, Calkins-Adams DP, Rinker LH, et al. Pimonidazole: A novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 1998;71:270–277
  25. Raleigh JA, Calkins-Adams DP, Rinker LH, et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res. 1998;58:3765–3768
  26. Wijffels KIEM, Kaanders JHAM, Rijken PFJW, et al. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br J Cancer. 2000;83:674–683
  27. Evans SM, Hahn S, Pook DR, et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res. 2000;60:2018–2024
  28. Olive PL, Durand RE. Detection of hypoxic cells in a murine tumor with the use of the comet assay. J Natl Cancer Inst. 1992;84:707–711
  29. Olive PL, Durand RE, Jackson SM, et al. The comet assay in clinical practice. Acta Oncol. 1999;38:839–844
  30. Grunbaum Z, Freauff SJ, Krohn KA, et al. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med. 1987;28:68–75
  31. Rasey JS, Grunbaum Z, Magee S, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res. 1987;111:292–304
  32. Rasey JS, Nelson NJ, Chin L, et al. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res. 1990;122:301–308
  33. Lim JL, Berridge MS. An efficient radiosynthesis of [18F]fluoromisonidazole. Appl Radiat Isot. 1993;44:1085–1091
  34. Rasey JS, Hofstrand PD, Chin LK, et al. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med. 1999;40:1072–1079
  35. Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology. 1995;194:795–800
  36. Kachur AV, Dolbier WR, Evans SM, et al. Synthesis of new hypoxia markers EF1 and [18F]-EF1. Appl Radiat Isot. 1999;51:643–650
  37. Evans SM, Kachur AV, Shiue CY, et al. Non-invasive detection of tumor hypoxia using the 2-nitroimidazole [18F]-EF1. J Nucl Med. 2000;41:327–336
  38. Dolbier WR, Li AR, Koch CJ, et al. [18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure. Appl Radiat Isot. 2001;54:73–80
  39. Chapman JD, Schneider RF, Urbain JL, et al. Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation. Semin Radiat Oncol. 2001;11:47–57
  40. Mannan RH, Somayaji VV, Lee J, et al. Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): A novel marker of tissue hypoxia. J Nucl Med. 1991;32:1764–1770
  41. Stypinski D, Wiebe LI, Mercer JR. A rapid and simple assay to determine the blood and urine concentrations of 1-(5-[123/125I] iodo-5-deoxyarabinofuranosyl)-2-nitroimidazole, a hypoxic cell marker. J Pharmaceut Biomed Anal. 1998;16:1067–1073
  42. Lee HC, Kumar P, McEwan AJ, et al. Synthesis, radiolabeling, and biodistribution of putative metabolites of iodoazomycin arabinoside. Nucl Med Biol. 2000;27:61–68
  43. Kumar P, Atrazheva E, Tandon M, et al. An improved synthesis of α-AZA, α-AZP and α-AZG, the precursors to clinical markers of tissue hypoxia. Tetrahedron Lett. 2001;42:2077–2078
  44. Schneider RF, Engelhardt EL, Stobbe CC, et al. The synthesis and radiolabeling of novel markers of tissue hypoxia of the iodinated azomycin nucleoside class. J Labelled Comp Radiopharm. 1997;39:541–557
  45. Chapman JD, Engelhardt EL, Stobbe CC, et al. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol. 1998;46:229–237
  46. Iyer RN, Haynes PT, Schneider RF, et al. Marking hypoxia in rat prostate carcinomas with D-[125I]azomycin galactopyranoside and [99mTc]HL-91: Correlation with microelectrode measurements. J Nucl Med. 2001;42:337–344
  47. Cherif A, Wallace S, Yang DJ, et al. Development of new markers for hypoxic cells: [131I]iodomisonidazole and [131I]-iodoerythronitroimidazole. J Drug Target. 1996;4:31–39
  48. Linder KE, Chan YW, Cyr JE, et al. TcO(PnAO-1-[2-nitroimidazole]) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: Synthesis, characterization, and xanthine oxidase-catalyzed reduction. J Med Chem. 1994;37:9–17
  49. Ballinger JR, Wan Min Kee J, Rauth AM. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med. 1996;37:1023–1031
  50. Melo T, Hua HA, Ballinger JR, et al. Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazale, with unlabelled nitroaromatics. Biochem Pharmacol. 1997;54:685–693
  51. (abstr) Barron B, Grotta J, Lamki L, et al. Preliminary experience with technetium-99m BMS-181321, a nitroimidazole, in the detection of cerebral ischemia associated with acute stroke. J Nucl Med. 1996;37:272P–273P
  52. Melo T, Duncan J, Ballinger JR, et al. BRU59-21, a secondgeneration technetium-99m-labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med. 2000;41:169–176
  53. Melo T, Ballinger JR, Rauth AM. Role of NADPH cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia. Biochem Pharmacol. 2000;60:625–634
  54. Su ZF, Zhang X, Ballinger JR, et al. Synthesis and evaluation of two technetium-99m-labeled peptidic 2-nitroimidazoles for imaging hypoxia. Bioconjugate Chem. 1999;10:897–904
  55. Zhang X, Su ZF, Ballinger JR, et al. Targeting hypoxia in tumors using 2-nitroimidazoles with peptidic chelators for technetium-99m: Effect of lipophilicity. Bioconjugate Chem. 2000;11:401–407
  56. Su ZF, Ballinger JR, Rauth AM, et al. A novel amine-dioxime chelator for technetium-99m: Synthesis and evaluation of 2-nitroimidazole-containing analogues as markers for hypoxic cells. Bioconjugate Chem. 2000;11:652–663
  57. Yang DJ, Ilgan S, Higuchi T, et al. Noninvasive assessment of tumor hypoxia with 99mTc labeled metronidazole. Pharmaceut Res. 1999;16:743–750
  58. Murugesan S, Shetty SJ, Noronha OPD, et al. Technetium-99m-cyclam AK 2123: A novel marker for tumor hypoxia. Appl Radiat Isot. 2001;54:81–88
  59. Mathias CJ, Green MA, Morrison WB, et al. Evaluation of Cu-PTSM as a tracer of tumor perfusion: Comparison with labeled microspheres in spontaneous canine neoplasms. Nucl Med Biol. 1994;21:83–87
  60. Fujibayashi Y, Taniuchi H, Yonekura Y, et al. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155–1160
  61. Dearling JLJ, Lewis JS, McCarthy DW, et al. Redox-active metal complexes for imaging hypoxic tissues: Structure-activity relationships in copper(II) bis(thiosemicarbazone) complexes. Chem Commun. 1998;1998:2531–2532
  62. Dearling JLJ, Lewis JS, Mullen GED, et al. Design of hypoxiatargeting radiopharmaceuticals: Selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med. 1998;25:788–792
  63. Blower PJ, Dilworth JR, Maurer RI, et al. Towards new transition metal-based hypoxic selective agents for therapy and imaging. J Inorg Biochem. 2001;85:15–22
  64. Lewis JS, McCarthy DW, McCarthy TJ, et al. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999;40:177–183
  65. Archer CM, Edwards B, Kelly JD, et al. Technetium-labeled agents for imaging tissue hypoxia in vivo. In: Nicolini M, Bandoli G, Mazzi U editor. Technetium and Rhenium in Chemistry and Nuclear Medicine. Padova: SG Editorali; 1995;p. 535–539
  66. (abstr) Brauers G, Archer CM, Burke JF. The chemical characterisation of the tumor imaging agent 99mTc-HL91. Eur J Nucl Med. 1997;24:943
  67. Zhang X, Melo T, Ballinger JR, et al. Studies of 99mTc-BnAO (HL-91): A non-nitroaromatic compound for hypoxic cell detection. Int J Radiat Oncol Biol Phys. 1998;42:737–740
  68. Yutani K, Kusuoka H, Fukuchi K, et al. Applicability of 99mTc-HL91, a putative hypoxic tracer, to detection of tumor hypoxia. J Nucl Med. 1999;40:854–861
  69. Honess DJ, Hill SA, Collingridge DR, et al. Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo. Int J Radiat Oncol Biol Phys. 1998;42:731–735
  70. Tatsumi M, Yutani K, Kusuoka H, et al. Technetium-99m HL91 uptake as a tumor hypoxia marker: Relationship to tumor blood flow. Eur J Nucl Med. 1999;26:91–94
  71. Siim B, Laux WT, Rutland MD, et al. Scintigraphic imaging of the hypoxia marker 99mtechnetium-labeled 2,2′(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; Prognox): Noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Res. 2000;60:4582–4588
  72. Horiuchi K, Tsukamoto T, Saito M, et al. The development of 99mTc-analog of Cu-DTS as an agent for imaging hypoxia. Nucl Med Biol. 2000;27:391–399
  73. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [18F]-fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199–212
  74. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;33:391–398
  75. Valk PE, Mathis CA, Prados MD, et al. Hypoxia in human glioblastoma: Demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med. 1992;33:2133–2137
  76. Yeh SH, Liu RS, Wu LC, et al. Fluorine-18 fluoromisonidazole tumor to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med. 1996;23:1378–1383
  77. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417–428
  78. Stypinski D, Wiebe LI, McEwan AJ, et al. Clinical pharmacokinetics of 123I-IAZA in healthy volunteers. Nucl Med Commun. 1999;20:559–567
  79. Parliament MB, Chapman JD, Urtasun RC, et al. Non-invasive assessment of human tumor hypoxia with 123I-iodoazomycin arabinoside: Preliminary report of a clinical study. Br J Cancer. 1992;65:90–95
  80. Groshar D, McEwan AJB, Parliament MB, et al. Imaging tumor hypoxia and tumor perfusion. J Nucl Med. 1993;34:885–888
  81. Urtasun RC, Parliament MB, McEwan AJ, et al. Measurement of hypoxia in human tumours by non-invasive SPECT imaging of iodoazomycin arabinoside. Br J Cancer. 1996;74:S209–S212
  82. Cook GJ, Houston S, Barrington SF, et al. Technetium-99m-labeled HL91 to identify tumor hypoxia: Correlation with fluorine-18-FDG. J Nucl Med. 1998;39:99–103
  83. (abstr) Versijpt J, D'Asseler Y, Moerman M, et al. 99m-Tc-labelled HL91, a novel marker of tissue hypoxia: A pilot study. Eur J Nucl Med. 2000;27:963
  84. Takahashi N, Fujibayashi Y, Yonekura Y, et al. Evaluation of 62Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med. 2000;14:323–328
  85. 34P Dehdashti F, Mintum MA, Lewis JS, et al. Evaluation of tumor hypoxia with Cu-60 ATSM and PET. (abstr) J Nucl Med. 2000;41:
  86. Kavanagh MC, Tsang V, Chow S, et al. A comparison in individual murine tumors of techniques for measuring oxygen levels. Int J Radiat Oncol Biol Phys. 1999;44:1137–1146
  87. Sinusas AJ. The potential for myocardial imaging with hypoxia markers. Semin Nucl Med. 1999;29:330–338
  88. Moreno-Merlo F, Nicklee T, Hedley DW. Association between tissue hypoxia and elevated non-protein sulphydryl concentrations in human cervical carcinoma xenografts. Br J Cancer. 1999;81:989–993
  89. Vukovic V, Pheng SR, Stewart A, et al. Protection from radiation-induced DNA single-strand breaks by induction of nuclear metallothionein. Int J Radiat Biol. 2000;76:757–762
  90. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 1995;36:1625–1632
  91. Minn H, Clavo AC, Fisher SJ, et al. Effect of nitroimidazole sensitizers on in vitro glycolytic metabolism of hypoxic squamous cell carcinoma. Acta Oncol. 2000;39:199–205
  92. Robinson SP, Howe FA, Rodrigues LM, et al. Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow. Semin Radiat Oncol. 1998;8:197–207
  93. Conover DL, Fenton BM, Foster TH, et al. An evaluation of near infrared spectroscopy and cryospectrophotometry estimates of haemoglobin oxygen saturation in a rodent mammary tumor model. Phys Med Biol. 2000;45:2685–2700
  94. Aboagye EO, Kelson AB, Tracy M, et al. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl)acetamide (SR4554/CRC 94/17): A non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography. Anti-Cancer Drug Des. 1998;13:703–730
  95. Tome WA, Fowler JF. Selective boosting of tumor subvolumes. Int J Radiat Oncol Biol Phys. 2000;48:593–599
  96. von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol. 2000;18:1351–1359
  97. Dachs GU, Coralli C, Hart SL, et al. Gene delivery to hypoxic cells in vitro. Br J Cancer. 2000;83:662–667
  98. Bussink J, Kaanders JH, van Der Kogel AJ. Clinical outcome and tumor microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide. Acta Oncol. 1999;38:875–882

PII: S0001-2998(01)80011-8

doi: 10.1053/snuc.2001.26191

Seminars in Nuclear Medicine
Volume 31, Issue 4 , Pages 321-329 , October 2001

Article Tools